James Rowe, MD, PhD is a British neurologist and professor at the University of Cambridge specializing in progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and cognitive impairment in neurodegenerative diseases. He leads the Cambridge PSP Research Clinic and is recognized internationally for his contributions to understanding tauopathies.
Professor Rowe's research spans several interconnected areas:
With over 150 peer-reviewed publications, Dr. Rowe's work has been pivotal in[1][2][3]:
Dr. Rowe's recent work (2024-2025) has focused on blood-based biomarkers, tau PET imaging, and presymptomatic detection in genetic FTD[4][5][3:1]:
| Institution | Role | Years |
|---|---|---|
| University of Cambridge | Professor of Neurology | 2018-Present |
| Cambridge University Hospitals NHS Foundation Trust | Consultant Neurologist | 2015-Present |
| MRC Cognition and Brain Sciences Unit, Cambridge | Senior Researcher | 2012-2018 |
Respondo D, et al., Rowe JB. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology. 2020. ↩︎
Volonte N, et al., Rowe JB. Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results. Alzheimer's & Dementia. 2024. ↩︎
Smith R, et al., Rowe JB. Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-beta status, APOE genotype and sex. Nature Neuroscience. 2025. ↩︎ ↩︎
Rohrer JD, Bocchetta M, et al., Rowe JB. Novel blood-based proteomic signatures across multiple neurodegenerative diseases. Alzheimer's & Dementia. 2025. ↩︎
Vandenberghe R, et al., Rowe JB. Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference. Alzheimer's & Dementia. 2025. ↩︎